Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)

Market Cap	4.83B +25.8%
Revenue (ttm)	1.24B +17.4%
Net Income	123.17M +639.1%
EPS	0.23 +527.2%
Shares Out	581.69M
PE Ratio	36.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,909,418
Open	7.71
Previous Close	8.18
Day's Range	7.71 - 8.46
52-Week Range	7.08 - 11.98
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:300016

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. It provides contrast agents, such as Iohexol injection, Gadolinol injection, Gadopentetate Dimeglumine injection, Iodixanol injection, and Iopamidol injection; Jiuweizhenxin granule, a central nervous system product; and oral anti-diabetic drugs, including Glimepiride tablets and Repaglinide tablets. The company was founded in 1992 and is based in Beijing, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,188
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300016

Financial Performance

In 2025, SHE:300016's revenue was 1.21 billion, an increase of 22.54% compared to the previous year's 983.55 million. Earnings were 92.73 million, an increase of 579.29%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error